Does protracted antiviral therapy impact on HCV-related liver cirrhosis progression?

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 36

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

201

HTML

1273

Figures (1-2)

132

Tables (1-2)

150

Sum=1756

Sep 28, 2007 (publication date) through Apr 25, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Sep 28, 2007; 13(36): 4903-4908
Published online Sep 28, 2007. doi: 10.3748/wjg.v13.i36.4903

Table 1 Laboratory and sonographic parameters of the population at entry

ALT: alanine aminotransferase; Chol: total cholesterol; Plts: platelets; SLD: splenic longitudinal diameter; US: ultra sound; SD: standard deviation.

¹P = 0.97 at unpaired T test;

²P = 0.72 at Mann-Whitney (M-W) test;

³P = 0.15, at M-W test;

⁴P = 0.65 at M-W test.

Citation: Tarantino G, Gentile A, Capone D, Basile V, Tarantino M, Minno MNDD, Cuocolo A, Conca P. Does protracted antiviral therapy impact on HCV-related liver cirrhosis progression? World J Gastroenterol 2007; 13(36): 4903-4908
URL: https://www.wjgnet.com/1007-9327/full/v13/i36/4903.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i36.4903